Nivolumab/Ipilimumab Improves Survival Versus Sunitinib in mRCC – OncLive
OncLive |
Nivolumab/Ipilimumab Improves Survival Versus Sunitinib in mRCC
OncLive In those with PD-L1 expression ≥1%, the Median PFS was significantly longer with the immunotherapy combination than with sunitinib (22.9 vs 5.9 months; HR, 0.48; P = .0003). Those with PD-L1 expression <1% did not benefit from the combination (HR, … Nivolumab cuts relapse by one third compared to Ipilimumab Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma |
